Although drug development is expensive, the high prices being charged for some specialty drugs, like Sovaldi, are not required to induce innovation, Len M. Nichols, PhD, wrote Monday for Morning Consult.
director of the Center for Health Policy Research and Ethics
Although drug development is expensive, the high prices being charged for some specialty drugs, like Sovaldi, are not required to induce innovation, Len M. Nichols, PhD, at George Mason University, wrote Monday for Morning Consult.
The high cost of complex drugs, often targeted to small patient populations, are unaffordable for the individual patients and the government. Despite making up just 1% of prescriptions writte, specialty drugs accounted 25% of drug spending in 2013, according to Dr Nichols, with spending on these medications growing faster than for all other drugs. It's estimated that by 2019 specialty drug spend will account for more than half of all drug spending.
"So what price we should pay for specialty drugs? High enough to keep productive R&D investment flowing into a risky and vital industry, but not whatever the successful companies want to charge just because they can," Dr Nichols wrote.
Read the full post at Morning Consult: http://bit.ly/1J0kIFZ
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More